THIS REPORT CONTAINS

An overview as to how the RNAi (ribonucleic acid interference) technologies market is applied in therapeutics, research and development (functional genomics, metabolism), drug discovery and agriculture
Analysis of global market trends, with data from 2009, estimates for 2010, and projections of compound annual growth rates (CAGRs) through 2015
Discussion of how the markets for RNAi are difficult to define as no RNAi-based product is in clinical development yet, and that the major use of RNAi reagents is in research but partially overlaps that of drug discovery and therapeutic development

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This BCC Research report, RNAI Drug Delivery: Technologies and Global Markets, provides an in-depth assessment of recent progress and future opportunities for RNA interference (RNAi) players in major therapeutic and drug delivery areas, including infectious diseases, cancer, inflammation/immune dysfunction, central nervous system (CNS) disorders, and cardiology/metabolism. The latest trends in RNAi therapeutics are examined, focusing on the main areas of clinical need, general/proprietary technologies, and company pipelines, and the activities and strategies of RNAi-based therapeutic companies are profiled. This report also provides forecasts for market growth to 2015 across RNAi market segments, reviews the latest advances in RNAi drug delivery technologies, and assesses the competitive landscape across RNAi therapeutic areas.

REASONS FOR DOING THE STUDY

Since its discovery in 1998 by two scientists, the naturally occurring RNA interference effect has been hailed as the hottest technical breakthrough in biological research. It may even surpass polymerase chain reaction (PCR) as a top technology. RNA interference allows scientists to silence the expression or effect of a gene being studied. Known simply as RNAi, this field has rapidly emerged as a fast-growing new market. This report assesses this emerging commercial market and maps the key RNAi therapeutic and drug delivery players on the market landscape. The initial companies produced reagents and kits for the biological research reagents market to support basic and applied research in academia, government, and industry. A number of companies decided to take the long road to develop therapeutics. Others have developed drug delivery approaches for emerging RNAi therapeutics. This report analyzes emerging RNAi molecules and delivery technologies and examines new molecular targets and pipeline drugs. It also evaluates competitors and collaborators in the developing RNAi technologies and examines the latest RNAi-related patenting trends.

SCOPE OF REPORT

The latest trends in RNAi therapeutics are examined, focusing on the main areas of clinical need, general/proprietary technologies, and company pipelines, and the activities and strategies of RNAi-based developers are profiled. This report also provides forecasts for market growth to 2015 across major RNAi market segments. This report provides an in-depth assessment of recent progress and future opportunities for RNAi players in major therapeutic areas.

INTENDED AUDIENCE

This report is an exhaustive study on the worldwide RNAi therapeutic and drug delivery market, giving crucial statistics and analysis on the delivery technologies, market structure, market size, key drug segments, important trends in technology development, major opportunities, and market shares of key players and drugs. This report may prove crucial for the firms or investors seeking engagement in the concerned sector. RNA interference continues to offer significant promise for a host of therapeutic treatments. Potentially any disease-causing gene, cell type, or tissue can be targeted with RNAi, including those not “druggable” with small molecules or protein-based therapies. Pharma companies are increasingly investing in small interfering RNA (siRNA) optimization or examining siRNA alternatives in addition to staking out proprietary positions in lipid-based, nanotransporter-based, and alternative delivery technologies. The development and licensing of such platforms will become crucial for developers over the coming years.

METHODOLOGY

Both primary and secondary research methodologies, interviews with key players in the RNAi field were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to paid databases. The base year of the report is 2009, with forecast data provided through 2015. Historical, base year and forecast data are provided for each market segment of this report. Growth rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in research and development (R&D), and current product growth, etc. 

Table Of Contents

Chapter- 1: INTRODUCTION

STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
SCOPE OF REPORT 1
INTENDED AUDIENCE 2
METHODOLOGY 2
RELATED BCC STUDIES 2
ANALYST CREDENTIALS 3
BCC ONLINE SERVICES 3
DISCLAIMER 3

Chapter-2: SUMMARY

SUMMARY 4
    SUMMARY TABLE GLOBAL MARKET FOR RNAI DRUG DELIVERY TECHNOLOGIES, THROUGH 2015 ($ MILLIONS) 5
SUMMARY FIGURE GLOBAL MARKET FOR RNAI DRUG DELIVERY TECHNOLOGIES, 2009-2015 ($ MILLIONS) 6

Chapter-3: OVERVIEW

OVERVIEW 7
THE PROMISE OF RNAI 8
    TABLE 1 VARIOUS TECHNOLOGIES FOR GENE SUPPRESSION 8
RNAI TECHNOLOGY 9
RNAI MECHANISM: -HOW DOES IT WORK? 10
WHY SIRNA THERAPEUTICS? 11
SIRNA DELIVERY 12
RNAI DESIGN AND METHODS 13
Barriers to Delivery 14
Cellular Uptake and siRNAs 15
siRNA Delivery and Challenges 15
COMMERCIAL INTEREST 16
LIPOSOME-BASED DELIVERY 17
NONLIPOSOMAL METHODS 18
Nucleic-Acid Aptamers 18
Aptamers as Therapeutics 19
   TABLE 2 THERAPEUTICALLY TARGETED APTAMERS 19
   TABLE 2 (CONTINUED) 20
Aptamers for siRNA Delivery 21
Challenges-Aptamer-siRNA Delivery 22
Challenges-Aptamer-siRNA … (Continued) 23
Commercial Interest for Aptamers 24
ANTISENSE THERAPY 24
Selected Companies 25
CLASSES OF ENDOGENOUS SMALL RNAS 26
siRNA and rasiRNA 26
siRNA and rasiRNA (Continued) 27
miRNA 28
OUTLOOK 29

Chapter-4: RNAI DRUG DELIVERY

RNAI DISCOVERED 30
IMPORTANCE OF DELIVERY FOR RNAI THERAPEUTICS 31
DRUG DELIVERY TECHNOLOGIES 31
   TABLE 3 ROLE OF DRUG DELIVERY 32
NEED FOR NEW TECHNLOGIES 33
RNAI DELIVERY-TOOL FOR DRUG DISCOVERY AND DEVELOPMENT 33
siRNA Screening 34
shRNA Screening 34
CHALLENGES TO OVERCOME IN DELIVERING RNAI 35
   TABLE 4 DIFFERENT RNAI DELIVERY APPROACHES 35
DIFFERENT DELIVERY TECHNIQUES 36
VECTOR-BASED DELIVERY 36
VECTOR-BASED RNAI FOR IN VIVO RNAI EXPERIMENTS 36
   TABLE 5 COMPANIES WITH PLASMID RNAI VECTORS 37
Viral Vectors for Delivery of siRNA 37
   TABLE 6 RNAI VIRAL VECTOR DELIVERY METHODS 38
   TABLE 7 LENTIVIRAL DELIVERY PRODUCTS AND COMPANIES 38
NONVIRAL SIRNA DELIVERY 38
Hydrodynamic IV Injection 39
Electroporation 39
CARRIER-MEDIATED DELIVERY 39
Lipid-based siRNA Delivery 39
Lipid-based siRNA delivery (Continued) 40
Polymer-Based siRNA Delivery 41
Combined Lipid and Polymer Carriers for a Better siRNA Delivery 42
Peptide-Mediated siRNA Delivery 43
Antibody-Mediated siRNA Delivery 44
Dendrimer-Mediated siRNA Delivery 45
Stem-cell-based Delivery 45
Light Controllable Delivery of siRNA 45
PROPRIETARY DELIVERY PLATFORMS 46
SYSTEMIC DELIVERY STRATEGIES 47
   TABLE 8 THERAPEUTIC STRATEGIES 48
LOCALIZED DELIVERY 48
Targeted Cellular Delivery 49
EXPRESSION-BASED STRATEGIES 50
RNAI DELIVERY AND IMPACT ON THERAPEUTIC DEVELOPMENTS 51
New Developments 52
New Developments (Continued) 53
Tissue Delivery 54
RNAi as Drugs 55
CURRENT NONBIOLOGICAL DELIVERY VEHICLES FOR SIRNAS 56
Simple Excipients 56
   TABLE 9 SIMPLE EXCIEPIENTS FOR RNAI DELIVERY 56
TRANSFECTION TECHNIQUES 57
Electroporation 57
Conjugates 57
   TABLE 10 CONJUGATES, PEPTIDES, AND PROTEINS, OTHERS 57
Peptides and Proteins 58
Dynamic Polyconjugate Transfection 58
Polymer Carriers/Nanoparticles 58
Polymer Carriers/Nanoparticles (Continued) 59
   TABLE 11 POLYMER CARRIERS/NANOPARTICLES FOR RNAI DELIVERY 60
Liposomes and Lipoplexes 61
   TABLE 12 LIPOSOMES/LIPOPLEXES AND RNAI DELIVERY 62
Case Study-siRNA in Mammalian Cells 62
Gene Silencing (RNAi) in Neuronal Cells 62
Concerns about RNAi Delivery 63
KEY COMPANIES 63
siRNA Transfection 63
   TABLE 13 COMPANIES INVOLVED IN DRUG DELIVERY TECHNOLOGIES FOR SIRNA 64
Delivery as Particles or Complexes 65
Delivery with Modifications 65
SUMMARY 66
Summary (Continued) 67

Chapter-5: RNAI-BASED THERAPEUTICS

RNAI-BASED THERAPEUTICS: THE EMERGING INDUSTRY LANDSCAPE 68
DELIVERING RNAI THERAPEUTICS 69
Delivering RNAi Therapeutics (Continued) 70
RNAi and Cancer Therapeutics 71
REGULATORY CONCERNS 71
Regulatory Concerns (Continued) 72
RNAI IN CLINICAL TRIALS 73
Clinical RNAi Pipeline 73
   TABLE 14 THE GLOBAL RNA INTERFERENCE THERAPEUTIC PIPELINE 73
   TABLE 14 (CONTINUED) 74
Clinical RNAi Pipeline (Continued) 75
Clinical RNAi Pipeline (Continued) 76
THE MOST ADVANCED RNAI CANDIDATE 77
Alnylam’s ALN-RSV: Respiratory Syncytial Virus 77
ALN-RSV01 Treatment of Respiratory Syncytial Virus Infection in Lung Transplant Patients 78
THERAPEUTIC RNAI-RECENT DEVELOPMENTS 79
Case Study-ALN-VSP02 79
Case Study-ALN-VSP02 (Continued) 80
SNALP Delivery 81
Other Candidates in Clinical Trials 82
Other Candidates in Clinical … (Continued) 83
Unexpected Problems and Possible Solutions for RNAi-Based Therapies 84
Unexpected Problems and … (Continued) 85

Chapter-6: RNAI LANDSCAPE

FUTURE TRENDS 86
WHAT IS RNA INTERFERENCE? 87
Locked Nucleic Acid 87
RNAI AS A RESEARCH TOOL 87
THE IMPORTANCE OF RNAI DESIGN 88
FACTS AND TIMELINES 88
MARKET GROWTH 89
GLOBAL MARKET FOR RNAI 89
   TABLE 15 GLOBAL RNAI RESEARCH SALES AND FORECAST, THROUGH 2015 ($ MILLIONS) 90
FIGURE 1 GLOBAL RNAI RESEARCH SALES, 2008-2015 ($ MILLIONS) 90
   TABLE 16 GLOBAL TOTAL MARKET FOR RNAI, THROUGH 2015 ($ MILLIONS) 91
FIGURE 2 GLOBAL TOTAL MARKET FOR RNAI, 2009-2015 ($ MILLIONS) 91
RNAI TECHNOLOGIES/PRODUCTS IN RESEARCH APPLICATIONS 92
RNAi Screening for Drug Discovery 93
Individual versus Pooled siRNAs 94
Necessary Controls 94
High-Throughput siRNA Delivery 95
High-Throughput siRNA … (Continued) 96
RNAI TOOL AND REAGENT MARKET 97
Transfection Products 97
Key Companies 98
…TABLE 17 RNAI COMPANIES WITH TRANSFECTION REAGENTS 98
…TABLE 17 (CONTINUED 99
RNAi Reagents 100
Lipid Transfection 101
In Vivo Reagents and Therapeutics 101
RNAi Experiments in Animals 102
RNAI AND THERAPEUTICS 103
   TABLE 18 IN VIVO DELIVERY 104
Viral-based Transfections 105
   TABLE 19 VIRAL BASED DELIVERY TECHNOLOGIES 106
Other Methods 106
RNAi Reagents and Kits 107
   TABLE 20 RNAI TOOL/REAGENT COMPANIES 108
   TABLE 20 (CONTINUED) 108
KEY COMPANIES 109
Thermo Fisher 109
Thermo Fisher (Continued) 110
Invitrogen-Results of Operations 111
   TABLE 21 INVITROGEN-REVENUES FOR THE FIRST 6 MONTHS, 2009-2010 (MILLIONS) 111
Lonza 112
   TABLE 22 LONZA-REVENUES, 2009 ($ MILLIONS) 113
Lonza’s RNAi Products 113
THE FUTURE OF RNAI THERAPEUTICS 114

Chapter-7: RNAI DRUG DELIVERY-MARKET DATA

MARKET SIZE AND GROWTH 115
DRUG DELIVERY TECHNOLGIES AND MARKET 115
GLOBAL PHARMACEUTICAL MARKET 115
TABLE 23 GLOBAL PHARMACEUTICAL SALES, THROUGH 2015 ($ BILLIONS) 116
FIGURE 3 GLOBAL PHARMACEUTICAL SALES, 2008-2015 ($ BILLIONS) 116
UNITED STATES PHARMACEUTICAL INDUSTRY 117
TOP 20 PHARMACEUTICAL COMPANIES IN 2009 117
TABLE 24 TOP 20 PHARMACEUTICAL COMPANIES, 2009 ($ MILLIONS: BASED ON 2008 SALES) 117
TABLE 24 (CONTINUED) 117
TABLE 25 TOP 20 PHARMACEUTICAL COMPANIES, 2010 ($ MILLIONS: BASED ON 2009 SALES)) 118
TABLE 26 TWELVE LARGEST PHARMACEUTICAL COMPANIES, 2010 ($ MILLIONS) 119
DRUG DELIVERY MARKET 119
GLOBAL MARKET 120
TABLE 27 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 120
FIGURE 4 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 ($ MILLIONS) 121
TABLE 28 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 122
FIGURE 5 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 ($ MILLIONS) 122
ORAL DRUG DELIVERY 122
TABLE 29 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 123
FIGURE 6 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 ($ MILLIONS) 123
TABLE 30 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 124
PULMONARY DRUG DELIVERY 124
FIGURE 7 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, 2009-2015 ($ MILLIONS) 125
IMPLANTABLE AND INJECTABLE DRUG DELIVERY 126
TABLE 31 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, THROUGH 2015 ($ MILLIONS) 126
FIGURE 8 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, 2009-2015 ($ MILLIONS) 126
TRANSDERMAL DRUG DELIVERY 127
TABLE 32 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 127
FIGURE 9 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 ($ MILLIONS) 128
U.S. Market 128
TABLE 33 U.S. DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 128
FIGURE 10 U.S. DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 ($ MILLIONS) 129
RNAI MARKET ANALYSIS 129
RNAI NUCLEIC ACID DRUG DELIVERY MARKET 130
TABLE 34 GLOBAL RNAI DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 130
FIGURE 11 GLOBAL RNAI DRUG DELIVERY TECHNOLOGIES MARKET, 2007-2015 ($ MILLIONS) 131
Aptamers and RNAi Market 131
TABLE 35 GLOBAL APTAMERS THERAPEUTIC MARKET, THROUGH 2015 ($ MILLIONS) 132
FIGURE 12 GLOBAL APTAMERS THERAPEUTIC MARKET, THROUGH 2015 ($ MILLIONS) 133
TARGETED DELIVERY 133
THE TOTAL NANOPARTICLE MARKET 133
TABLE 36 GLOBAL NANOPARTICLE DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 134
FIGURE 13 GLOBAL NANOPARTICLE DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 ($ MILLIONS) 134
TABLE 37 GLOBAL TARGETED DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 ($ MILLIONS) 135
FIGURE 14 GLOBAL TARGETED DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 ($ MILLIONS) 135
RNAI DELIVERY APPROACHES AND CURRENT DEVELOPMENTS 136
DEVELOPMENT OF RNAI-BASED THERAPEUTICS 137
Delivery of Therapeutics to the Target Tissues 138
RNAi Drugs under Investigation 139
Naked siRNA 139
Companies/Latest Developments 140
Lipid and Polymer-Based Systems 141
TABLE 38 LIPID-BASED TECHNOLOGIES-COMPANIES 141
TABLE 39 POLYMER-BASED AND LIPOSOMAL RNAI DELIVERY SYSTEMS (%) 142
RNAI INTO THE PATIENTS 143
Polyconjugate Technologies 144
Polymer-Based Systems—Limitations 145
Nanoparticles 145
TABLE 40 NANOPARTICLES TECHNOLOGIES-COMPANIES 146
Single siRNA Delivery 146
TABLE 41 SINGLE RNAI DELIVERY TECHNOLOGIES-COMPANIES 147
NEW DELIVERY TECHNOLOGIES 148
SYSTEMIC DELIVERY 149
SYSTEMIC DELIVERY STRATEGIES 149
Challenges with RNAi Drug Delivery 150
RNAI THERAPEUTIC MARKET 150
TABLE 42 SELECTED RNAI-BASED DRUGS IN DEVELOPMENT 151
COMMERCIAL POTENTIAL OF RNAI 151
RNAI’S THERAPEUTIC POTENTIAL 151
COMPANIES AND SIRNA 151
How Does RNAi Work? 152
RNAis and Preclinical Studies 153
CEQ508 in Clinic 154
RNAi as a Therapy 154
GLOBAL MARKET OF THERAPEUTIC RNAI 155
RNAi Therapeutic Market to Play a Key Role by 2020 155
TABLE 43 GLOBAL MARKET FOR THERAPEUTIC RNAI, THROUGH 2015 ($ MILLIONS) 156
FIGURE 15 GLOBAL MARKET FOR THERAPEUTIC RNAI, 2009-2015 ($ MILLIONS) 156
TABLE 44 RNAI THERAPEUTIC COMPANIES 157
TABLE 44 (CONTINUED) 158
MicroRNA and Market 158
TABLE 45 MICRORNA MARKET AND FORECAST, THROUGH 2015 ($ MILLIONS) 159
FIGURE 16 MICRORNA MARKET AND FORECAST, 2009-2015 ($ MILLIONS) 159
TABLE 46 TOTAL MIRNA MARKET SALES, 2008 (%) 159
RNAI LICENSING DEALS 160
TABLE 47 MAJOR RNAI LICENSING DEALS, 2005-2010 161
TABLE 47 (CONTINUED) 162
Recent Trends 162
Recent Trends (Continued) 163
New RNAi Delivery Technologies 164
TARGETED DELIVERY 164
TABLE 48 SYSTEMIC DELIVERY TECHNOLOGIES-COMPANIES 165
KEY THERAPEUTIC COMPANIES AND DEVELOPMENTS 166
TABLE 49 LEAD COMPANIES DEVELOPING RNAI-BASED DRUGS 167
TABLE 49 (CONTINUED) 167
ALNYLAM 168
TABLE 50 ALNYLAM PHARMACEUTICALS-NET REVENUE, 2009 AND 2010 ($ THOUSANDS) 169
Roche Alliance 169
TABLE 51 ALNYLAM’S TOTAL NET REVENUES FROM RESEARCH COLLABORATORS, 2009 AND 2010 ($ THOUSANDS) 170
Takeda Alliance 170
Other-Discovery and Development Alliances 171
Isis Collaboration 171
Novartis Broad Alliance 172
Product Alliances 173
Kyowa Hakko Kirin Alliance 173
Cubist Alliance 173
Government Funding 174
NIH Contract 174
TABLE 52 ALNYLAM’S DEVELOPMENT PIPELINE 175
TEKMIRA 175
Funding 175
Tekmira’s LNP Technology 176
TABLE 53 TEKMIRA’S DEVELOPMENT PIPELINE 177
Tekmira’s Pipeline 177
TKM-ApoB 177
TKM-PLK1 178
TKM-Ebola 179
Roche 180
Merck 180
Bristol-Myers Squibb 181
U.S. Army Medical Research Institute for Infectious Diseases (USAMRIID) Research Agreement 181
Takeda 181
Pfizer 181
TABLE 54 TEKMIRA’S PIPELINE 182
Revenue 182
TABLE 55 TEKIMIRA REVENUE ($ MILLIONS) 182
RXI PHARMACEUTICALS 183
Pipeline 183
TABLE 56 RXI PHARMACEUTICALS’ DEVELOPMENT PIPELINE 183
RXi Agreements 184
Philips 184
Other Collaborative Agreements 184
Scientific Achievements 184
NIH Grant 185
Financial Highlights 185
MARINA BIOTECH 185
Pipeline 186
TABLE 57 MARINA BIOTECH’S DEVELOPMENT PIPELINE 186
Revenue 186
TABLE 58 MARINA BIOTECH REVENUE, 2008 AND 2009 ($ THOUSANDS) 187
TABLE 59 MARINA BIOTECH REVENUE FROM CUSTOMERS AS A PERCENTAGE OF TOTAL REVENUE, 2008 AND 2009 (%) 187
Ongoing Collaborations 187
Beth Israel Deaconess Medical Center-Boston, Massachusetts 187
Institut Pasteur Paris, France 188
University of British Columbia (UBC)/Vancouver Prostate Centre (VPC)-Vancouver, British Columbia, Canada 188
University of Helsinki-Helsinki, Finland 188
TABLE 60 MARINA BIOTECH SELECTED COLLABORATIONS 188
CALANDO PHARMACEUTICALS 189
CALAA-01 190
ISIS PHARMACEUTICALS 190
Pipeline 190
TABLE 61 ISIS PHARMACEUTICALS DRUG DEVELOPMENT PIPELINE 191
Strategic Alliances 191
Pharmaceutical Partners 192
TABLE 62 ISIS PHARMACEUTICALS, REVENUE, 2009-2010 ($ THOUSANDS) 192
SILENCE THERAPEUTICS 192
Proprietary Delivery Technologies 193
Pipeline 194
TABLE 63 SILENCE THERAPEUTICS-DEVELOPMENT PIPELINE 194
Collaborations 195
AstraZeneca 195
Dainippon Sumitomo Pharma 195
Quark Pharmaceuticals 196
Financial Highlights 196
TABLE 64 SILENCE THERAPEUTICS-REVENUE, 2009 AND 2010 ($ MILLIONS) 196
QUARK PHARMACEUTICALS 196
Clinical Studies 197
TABLE 65 QUARK PHARMACEUTICALS CURRENT CLINICAL TRIALS 197
Pipeline 197
TABLE 66 QUARK PHARMACUETICALS-DEVELOPMENT PIPELINE 197
TABLE 66 (CONTINUED) 197
ROCHE 198
MERCK SERONO 199
SIRNAOMICS 200
ACCESS PHARMACEUTICALS 200
KEY MICRORNA THERAPEUTIC COMPANIES 201
MIRNA THERAPEUTICS 201
Pipeline 202
TABLE 67 MIRNA-DEVELOPMENT PIPELINE 202
REGULUS 203
Pipeline 203
Partnerships 204
LOCAL THERAPY 205
DRUG DELIVERY IN CANCER 206
RNAI MARKETPLACE CHALLENGES 207
RNAI’S GROWTH AND FUTURE 208

Chapter-8: GLOBAL MARKET FOR RNAI TECHNOLOGY

FUTURE 209
RNAI- DISCOVERY AND GROWTH 209
RNAI THERAPEUTICS FORECAST 210
COMPANY PROFILES 210
THERAPEUTIC COMPANIES 210
Alnylam Pharmaceuticals 210
Dicerna Pharmaceuticals 211
RXi Pharmaceuticals 212
ProNAi Therapeutics 212
Somagenics 213
DELIVERY COMPANIES 213
Sirnaomics 213
Calondo Pharmaceuticals 214
Tacere Therapeutics 214
PhaseRx 215
Marina Biotech 215
Tekmira 216
Isis Pharmaceuticals 216
Silence Therapeutics 216
Quark Pharmaceuticals 217
Merck 218
Access Pharmaceuticals 218
AparnaBio 219
Traversa Therapeutics 219
MICRORNA COMPANIES 220
Regulus 220
Asuragen 220
Mirna Therapeutics 221
REAGENT/TOOL COMPANIES 221
Ambion 221
Invitrogen 222
B-Bridge International 222
Bio-Rad Laboratories 222
Clontech Laboratories 222
Cyntellect 223
Dharmacon 223
Integrated DNA Technologies (IDT) 224
Genecopoeia 225
GeneThera 225
Genlantis 225
Genosensor 226
General Research Laboratory 226
Imgenex 227
Invivogen 227
New England Biolabs 227
Open Biosystems 228
Origene Technologies 228
Panomics 228
Promega Corporation 229
Sigma-Aldrich 229
System Biosciences 229
COMPANY PROFILES-EUROPE 230
ACTIGENICS SA 230
AMAXA 230
Cenix Bioscience Gmbh 231
GENOVIS 231
PROSENSA HOLDING 232
QIAGEN GMBH 232
RNAX GMBH (GERMANY) 232
SANTARIS PHARMA A/S 233
COMPANY PROFILES-ASIA-PACIFIC 233
ALPHAGEN 233
BENITEC 233
BIONEER 234
CYTOPATHFINDER, INC. 234
GENESIS RESEARCH and DEVELOPMENT CORP 235
KOKEN CO. LTD. 235
ONCOLYS BIOPHARMA, INC. 235
SHANGHAI GENEPHARMA CO. LTD. 236
SHANGHAI GENOMICS 236
TRANSGENE BIOTEK 237

Chapter-9: MARKET SHIFTS IN RNAI SPACE

MARKET SHIFTS IN RNAI SPACE 238
INTELLECTUAL PROPERTY AND PATENT ASPECTS 239
   TABLE 68 MAJOR RNAI COMPANIES IN THE US-PATENT DISTRIBUTION 240
FUTURE DEVELOPMENTS 240
SOME SELECTED PATENTS 240
RECENT PATENT NEWS 241
Recent Patent News (Continued) 242
Recent Patent News (Continued) 243
   TABLE 69 PATENTS 244
                                Recent Patent News (Continued) 245
Recent Patent News (Continued) 246
LICENSES FOR RNAI PATENTS 247
KEY COMPANIES AND PATENTS 247
ALNYLAM 247
RXI 248
ISIS 248
QUARK 249
BENITEC 249
PARTNERSHIPS, ALLIANCES, MERGERS, AND ACQUISITIONS 250
ALNYLAM COLLABORATORS: SIGNIFICANT NEW ADVANCES IN RNAI DELIVERY 250
Alnylam Collaborators: (Continued) 251
Alnylam, Medtronic, and CHDI Foundation 252
Alnylam, Medtronic, and … (Continued) 253
Alnylam and Tekmira 254
RECENT FUNDING 255
Marina Biotech Announces Financing for up to $8.7 Million 255
Tekmira and Collaborators Awarded $2.4 Million NIH Grant for Development of RNAi Therapeutics to Treat Ebola and Marburg Viral Infections 256
RXi Pharmaceuticals Awarded $1 Million in IRS Grants to Advanced RNAi Therapeutics 256
Sanofi-Aventis Completes $10 Million Equity Investment in Regulus Therapeutics 257
Tekmira Provides Update on NASDAQ Listing 258
CONCLUSIONS 259

Chapter-10: BIBLIOGRAPHY

BIBLIOGRAPHY 260

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Pulmonary Drug Delivery Systems: Technologies and Global Markets

Pulmonary Drug Delivery Systems: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Receive a detailed analysis of the present and future global market for pulmonary drug delivery technologies. - Receive information on pulmonary drug delivery technologies currently ...

RNAi Drug Delivery : Technologies and Gobal Markets

RNAi Drug Delivery : Technologies and Gobal Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research report provides an in-depth assessment of recent progress and future opportunities for RNA interference (RNAi) players in major therapeutic and drug delivery areas, including infectious ...

Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

  • $ 4 795
  • Industry report
  • May 2014
  • by Transparency Market Research

nebulizer is a medical device used for the treatment of respiratory disorders (asthma, COPD and cystic fibrosis) that converts liquid medication into mist or aerosol. Thus, the medicine can easily reach ...

Cytotoxic Drug Delivery

May 2014 $ 2 850

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.